keyword
MENU ▼
Read by QxMD icon Read
search

Immuno therapy

keyword
https://www.readbyqxmd.com/read/29037259/immuno-thermal-ablations-boosting-the-anticancer-immune-response
#1
REVIEW
Ryan Slovak, Johannes M Ludwig, Scott N Gettinger, Roy S Herbst, Hyun S Kim
The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have the potential to enhance the systemic anticancer immune effects induced by locoregional thermal ablation. The immune responses induced by ablation monotherapy are well documented, but independently they tend to be incapable of evoking a robust antitumor response. By adding immunomodulators to traditional ablative techniques, several researchers have sought to amplify the induced immune response and trigger systemic antitumor activity...
October 17, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29035086/notch-signaling-is-essential-for-maturation-self-renewal-and-tri-differentiation-of-in-vitro-derived-human-neural-stem-cells
#2
Katari Venkatesh, L Vinod Kumar Reddy, Salar Abbas, Madhubanti Mullick, Erfath Thanjeem Begum Moghal, Janardhana Papayya Balakrishna, Dwaipayan Sen
Although neural stem cells (NSCs) have potential applications in treating neurological disorders, much still needs to be understood about the differentiation biology for their successful clinical translation. In this study, we aimed at deriving NSCs from human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and explored the role of Notch signaling in the differentiation process. The hUCB-MSCs were characterized as per guidelines of the International Society of Cellular Therapy. NSCs were successfully generated from hUCB-MSCs by using epidermal and fibroblast growth factors under serum-free conditions...
October 16, 2017: Cellular Reprogramming
https://www.readbyqxmd.com/read/29033812/the-successful-use-of-a-novel-microwave-device-in-the-treatment-of-a-plantar-wart
#3
Ivan Robert Bristow, Christopher Webb, Michael Roger Ardern-Jones
Plantar warts, caused by the human papilloma virus (HPV), are a commonly encountered condition presenting in clinic. In adults, an array of various therapies exists, frequently with modest results particularly with plantar lesions. Microwaves have had limited uses for medical purposes. Recently a new portable microwave device has been approved for the treatment of skin lesions. Prior research has demonstrated immuno-stimulatory effects against HPV infection. We report the application of a novel portable medical microwave unit to treat a long-standing plantar wart which had failed to respond to other treatment modalities...
May 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29029813/innovative-therapy-monoclonal-antibodies-and-beyond
#4
M Di Nicola, L Apetoh, M Bellone, M P Colombo, G Dotti, S Ferrone, M Muscolini, J Hiscott, A Anichini, S M Pupa, F de Braud, M Del Vecchio
The seventh Edition of "Innovative Therapy, Monoclonal Antibodies and Beyond" Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting were focused on: 1) Preclinical assays and novel biotargets; and 2) monoclonal antibodies, cell therapies and targeted molecules. Between these two sessions, a lecture entitled "HLA-antigens modulation and response to immune checkpoint inhibitor immunotherapy" was also presented. Despite the impressive successes in cancer immunotherapy in recent years, the response to immune based interventions occurs only in a minority of patients (∼20%)...
October 5, 2017: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/29029482/in-vivo-immuno-targeting-of-an-extracellular-epitope-of-membrane-bound-preferentially-expressed-antigen-in-melanoma-prame
#5
Dmitry Pankov, Ludvig Sjöström, Teja Kalidindi, Sang-Gyu Lee, Kjell Sjöström, Rui Gardner, Michael R McDevitt, Richard O'Reilly, Daniel L J Thorek, Steven M Larson, Darren Veach, David Ulmert
Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed as an intracellular protein, we have demonstrated that PRAME has a membrane bound form with an external epitope targetable with conventional antibodies. We generated a polyclonal antibody (Membrane associated PRAME Antibody 1, MPA1) against an extracellular peptide sequence of PRAME...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29024776/update-on-tumor-infiltrating-lymphocytes-tils-in-breast-cancer-including-recommendations-to-assess-tils-in-residual-disease-after-neoadjuvant-therapy-and-in-carcinoma-in-situ-a-report-of-the-international-immuno-oncology-biomarker-working-group-on-breast-cancer
#6
REVIEW
Maria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M D'Alfonso, Sandra Demaria, Carlos Castaneda, Joselyn Sanchez, Sunil Badve, Stefan Michiels, Veerle Bossuyt, Federico Rojo, Baljit Singh, Torsten Nielsen, Giuseppe Viale, Seong-Rim Kim, Stephen Hewitt, Stephan Wienert, Sybille Loibl, David Rimm, Fraser Symmans, Carsten Denkert, Sylvia Adams, Sherene Loi, Roberto Salgado
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research...
October 9, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29022089/quantification-of-altered-tissue-turnover-in-a-liquid-biopsy-a-proposed-precision-medicine-tool-to-assess-chronic-inflammation-and-desmoplasia-associated-with-a-pro-cancerous-niche-and-response-to-immuno-therapeutic-anti-tumor-modalities
#7
REVIEW
Nicholas Willumsen, Louise B Thomsen, Cecilie L Bager, Christina Jensen, Morten A Karsdal
Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a need for novel biomarkers that can predict and monitor treatment. Tumor microenvironment alterations, more specifically the state of chronic inflammation and desmoplasia (tumor fibrosis), are important factors to consider in this context...
October 11, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29020960/perspectives-in-immunotherapy-meeting-report-from-the-immunotherapy-bridge-napoli-november-30th-2016
#8
Paolo A Ascierto, Bruno Daniele, Hans Hammers, Vera Hirsh, Joseph Kim, Lisa Licitra, Rita Nanda, Sandro Pignata
The complex interactions between the immune system and tumors lead the identification of key molecules that govern these interactions: immunotherapeutics were designed to overcome the mechanisms broken by tumors to evade immune destruction. After the substantial advances in melanoma, immunotherapy currently includes many other type of cancers, but the melanoma lesson is essential to progress in other type of cancers, since immunotherapy is potentially improving clinical outcome in various solid and haematologic malignancies...
October 11, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28994388/-cancer-three-eras-of-personalized-medicine
#9
Bertrand Jordan
Since the completion of the first human DNA sequence, genomic approaches have penetrated into cancer research and therapy: first through expression profiling for diagnostic, prognostic and predictive purposes, then by sequencing of tumour DNA in order to define and apply targeted therapies. These overlapping changes occurred quite rapidly and are now overshadowed by immuno-oncology approaches that show much promise. There is however still much left to understand to make this more widely applicable, and the extreme cost of these therapies is a serious concern...
October 2017: Médecine Sciences: M/S
https://www.readbyqxmd.com/read/28984367/host-microbiota-interplay-in-mediating-immune-disorders
#10
REVIEW
Krysta M Felix, Shekha Tahsin, Hsin-Jung Joyce Wu
To maintain health, the immune system must maintain a delicate balance between eliminating invading pathogens and avoiding immune disorders such as autoimmunity and allergies. The gut microbiota provide essential health benefits to the host, particularly by regulating immune homeostasis. Dysbiosis, an alteration and imbalance of the gut microbiota, is associated with the development of several autoimmune diseases in both mice and humans. In this review, we discuss recent advances in understanding how certain factors, such as age and gender, affect the gut microbiota, which in turn can influence the development of autoimmune diseases...
October 6, 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/28982322/pd-1-pd-l1-inhibitors-for-immuno-oncology-from-antibodies-to-small-molecules
#11
Qiaohong Geng, Peifu Jiao, Peng Jin, Gaoxing Su, Jinlong Dong, Bing Yan
BACKGROUND: The recent regulatory approvals of immune checkpoint protein inhibitors such as ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab ushered a new era in cancer therapy. These inhibitors do not attack tumor cells directly but instead mobilize the immune system to re-recognize and eradicate tumors, which endows them unique advantages including durable clinical responses and substantial clinical benefits. PD-1/PD-L1 inhibitors, a pillar of immune checkpoint protein inhibitors, have demonstrated unprecedented clinical efficacy in more than 20 cancer types...
October 4, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28978323/synergistic-oligodeoxynucleotide-strongly-promotes-cpg-induced-interleukin-6-production
#12
Shireen Nigar, Yoshinari Yamamoto, Takuma Okajima, Suguru Shigemori, Takashi Sato, Tasuku Ogita, Takeshi Shimosato
BACKGROUND: Bacterial genomes span a significant portion of diversity, reflecting their adaptation strategies; these strategies include nucleotide usage biases that affect chromosome configuration. Here, we explore an immuno-synergistic oligodeoxynucleotide (iSN-ODN, named iSN34), derived from Lactobacillus rhamnosus GG (LGG) genomic sequences, that exhibits a synergistic effect on immune response to CpG-induced immune activation. METHODS: The sequence of iSN34 was designed based on the genomic sequences of LGG...
October 4, 2017: BMC Immunology
https://www.readbyqxmd.com/read/28971564/small-molecules-drive-big-improvements-in-immuno-oncology-therapies
#13
Klaus Urbahns, Bayard R Huck, Lisa Kötzner
Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatment regimens. In order to further improve clinical response rates, researchers are looking for novel combination treatments, using checkpoint blockade as a backbone of the treatment. This review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.
October 3, 2017: Angewandte Chemie
https://www.readbyqxmd.com/read/28968287/establishing-a-rodent-model-of-ventricular-fibrillation-cardiac-arrest-with-graded-histologic-and-neurologic-damage-with-different-cardiac-arrest-durations
#14
Florian Ettl, Ingrid A M Magnet, Wolfgang Weihs, Alexandra Warenits, Daniel Grassmann, Michael Wagner, Ursula Teubenbacher, Sandra Högler, Fritz Sterz, Andreas Janata
PURPOSE: To establish a ventricular fibrillation (VF) cardiac arrest (CA) resuscitation model with consistent neurologic and neuropathologic damage as potential therapeutic target. METHODS: Prospectively randomized groups of experiments in 2 phases. In phase 1 four groups of male Sprague-Dawley rats (n = 5) were resuscitated after 6 min VFCA with 2 and 6 min basic life support durations (BLS) with and without adrenaline. In phase 2 the most promising group regarding return of spontaneous circulation (ROSC) and survival was compared to a group of 8 min CA...
September 28, 2017: Shock
https://www.readbyqxmd.com/read/28961038/focused-ultrasound-for-immuno-adjuvant-treatment-of-pancreatic-cancer-an-emerging-clinical-paradigm-in-the-era-of-personalized-oncotherapy
#15
Ezekiel Maloney, Tanya Khokhlova, Venu G Pillarisetty, George R Schade, Elizabeth A Repasky, Yak-Nam Wang, Lorenzo Giuliani, Matteo Spring, Joo Ha Hwang
Current clinical treatment regimens, including many emergent immune strategies (e.g., checkpoint inhibitors) have done little to affect the devastating course of pancreatic ductal adenocarcinoma (PDA). Clinical trials for PDA often employ multi-modal treatment, and have started to incorporate stromal-targeted therapies, which have shown promising results in early reports. Focused ultrasound (FUS) is one such therapy that is uniquely equipped to address local and systemic limitations of conventional cancer therapies as well as emergent immune therapies for PDA...
September 29, 2017: International Reviews of Immunology
https://www.readbyqxmd.com/read/28950816/maternal-immunomodulation-therapy-for-prevention-of-preterm-birth-and-prematurity-related-morbidity-the-new-era-of-immuno-perinatology
#16
Shriddha Nayak, Jared Welling, Irina Burd
Preterm birth and associated prematurity-related morbidity can significantly affect neonatal health and outcomes. While the mechanisms of preterm labor are yet to be fully understood, there is a need for prenatal therapeutic interventions to treat these conditions. As it is recognized from literature, the immune mechanisms responsible for preterm labor may be different from those responsible for prematurity-related conditions in the neonate. Differentiating the mechanisms for these two processes is yet to be addressed, and steps need to be taken to move forward the new field of immune-perinatology...
September 25, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28940439/detection-of-abcb5-tumour-antigen-specific-cd8-t-cells-in-melanoma-patients-and-implications-for-immunotherapy
#17
Sylvia Borchers, Christoph Masslo, Christina Ann Müller, Anika Tahedl, Jennifer Volkind, Yvonne Nowak, Viktor Umansky, Jasmina Esterlechner, Markus Hermann Frank, Christoph Ganss, Mark Andreas Kluth, Jochen Utikal
ABCB5 has been identified as a tumour initiating cell marker and is expressed in various malignancies, including melanoma. Moreover, treatment with anti-ABCB5 monoclonal antibodies has been shown to inhibit tumour growth in xenotransplantation models. Therefore, ABCB5 represents a potential target for cancer immunotherapy. However, cellular immune responses against ABCB5 in humans have not been described so far. Here, we investigated whether ABCB5-reactive T cells are present in human melanoma patients and tested the applicability of ABCB5-derived peptides for experimental induction of human T cell responses...
September 23, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28938090/small-molecule-targets-in-immuno-oncology
#18
REVIEW
Dashyant Dhanak, James P Edwards, Ancho Nguyen, Peter J Tummino
Advances in understanding the role and molecular mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clinical practice in the treatment of cancer. Presently, multiple biologic drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clinical development for many cancers. In addition, combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival...
September 21, 2017: Cell Chemical Biology
https://www.readbyqxmd.com/read/28935020/-novel-immuno-oncology-therapy-current-status-of-clinical-research-and-prospect-of-application
#19
Shijia Zhang, Shengxiang Ren
Recently, immune-oncologic therapy advanced rapidly and has been defined as another option, following surgery, radiotherapy, chemotherapy and molecular targeted therapy, for treatment of malignant diseases. To date, several immune checkpoint inhibitors and compounds have been approved to treat various of malignant diseases with efficiency. Meanwhile, more and more potential therapeutic targets in processes of the cancer immunity have been noticed. We aimed to summarize the research status and clinical prospects of novel immune-oncologic treatment agencies targeted to different steps of the cancer-immunity cycle...
September 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28922567/determination-of-pd-l1-expression-in-effusions-from-mesothelioma-by-immuno-cytochemical-staining
#20
Mohammed S I Mansour, Tomas Seidal, Ulrich Mager, Amir Baigi, Katalin Dobra, Annika Dejmek
BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death 1 (PD-1). PD-L1 is up-regulated in cancer cells, and the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion, thus providing a target for antitumor therapy. Further, a correlation between PD-L1 expression and prognosis has been reported...
September 18, 2017: Cancer
keyword
keyword
50563
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"